Goldman Sachs Maintains Buy Rating for NeoGenomics: Here's What You Need To Know
Portfolio Pulse from Benzinga Insights
Goldman Sachs has reaffirmed its Buy rating on NeoGenomics (NASDAQ:NEO), raising the price target from $17.00 to $19.00. Following this update, NeoGenomics' shares saw a 1.27% increase, trading at $16.69. The new price target suggests a potential 13.84% upside. NeoGenomics specializes in cancer-focused genetic testing services in the U.S. and Switzerland, with the majority of its revenue coming from Clinical Services.
February 22, 2024 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Goldman Sachs maintains a Buy rating on NeoGenomics, raising the price target from $17 to $19, indicating a bullish outlook. Shares increased by 1.27% to $16.69, with the new target suggesting a 13.84% upside.
The maintenance of a Buy rating and the increase in price target by a reputable financial institution like Goldman Sachs typically instills confidence in investors, potentially driving up the stock price in the short term. The 1.27% increase in share price following the announcement further supports this bullish outlook.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100